Evidence map›Paper›PMID 40940222›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Antibody targeting TDP-43 mitigates pathogenic pathways induced by the cerebrospinal fluid of ALS.

Amélie Poulin-Brière, Silvia Pozzi, Jean-Pierre Julien

Abstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amélie Poulin-BrièreCERVO Brain Research Center 2601 Chemin de la Canardière, Québec, QC G1J 2G3, Canada.
Silvia PozziCERVO Brain Research Center 2601 Chemin de la Canardière, Québec, QC G1J 2G3, Canada; Department of Psychiatry and Neuroscience, Laval University, Québec, QC G1V 0A6, Canada.
Jean-Pierre JulienCERVO Brain Research Center 2601 Chemin de la Canardière, Québec, QC G1J 2G3, Canada; Department of Psychiatry and Neuroscience, Laval University, Québec, QC G1V 0A6, Canada. Electronic address: jean-pierre.julien@fmed.ulaval.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease characterized by the cytoplasmic mislocalization and accumulation of TAR DNA binding protein 43 (TDP-43). We reported previously the protective effects in a transgenic mouse model expressing ALS-linked mutant TDP-43

Indexed as

Amyotrophic Lateral SclerosisAntibodies, MonoclonalDNA-Binding ProteinsAnimalsDisease Models, AnimalFemaleHumansMaleMiceMice, TransgenicMotor NeuronsSpinal CordAntibodies, MonoclonalDNA-Binding ProteinsTARDBP protein, humanAntibodyCSFSporadic ALSTDP-43Therapy

Identifiers

PMID40940222
PMCPMC12664456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.